GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget by $1.1 billion and cut its 2024 sales outlook.

Respiratory virus season is quickly approaching, meaning we will start to see cold, flu, COVID, and RSV in our community. The ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

Covid-19 cases are high in many parts of the U.S. and they’re continuing to rise. These numbers come as flu season is coming ...